MedTrace Logo

Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children

NCT04072276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 227

Last updated 2022-09-30

No results posted yet for this study

Summary

This study is designed to evaluate the long-term antibody titers of EV71 vaccine 4 and 5 years after first dose vaccination for subjects at the age of 2 to \< 6 years , and 3 to 5 years after first dose vaccination for subjects at the age of 2 months to \< 2 years

Conditions

  • Enterovirus 71 Human

Interventions

BIOLOGICAL

EV71 vaccine

EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study

Sponsors & Collaborators

  • Medigen Vaccine Biologics Corp.

    lead INDUSTRY

Principal Investigators

  • Li-Min Huang, M.D., Ph.D. · National Taiwan University Hospital

  • Cheng-Hsun Chiu, M.D., Ph.D. · Chang Gang Memorial Hospital, LinKou

  • Chien-Yu Lin, M.D., Ph.D. · Mackay Memorial Hospital, HsinChu

  • Nan-Chang Chiu, M.D. · Mackay Memorial Hospital

Eligibility

Min Age
2 Years
Max Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-08-15
Primary Completion
2021-12-11
Completion
2021-12-11

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04072276 on ClinicalTrials.gov